Article Text

Download PDFPDF
Short report
Prevalence of lymphogranuloma venereum among anorectal Chlamydia trachomatis-positive MSM using pre-exposure prophylaxis for HIV
  1. Olivia Peuchant1,2,3,
  2. Arabella Touati3,
  3. Cécile Laurier-Nadalié3,
  4. Nadege Hénin1,2,
  5. Charles Cazanave1,2,3,4,
  6. Cécile Bébéar1,2,3,
  7. Bertille de Barbeyrac1,2,3
  1. 1Univ. Bordeaux, USC EA3671, Mycoplasmal and Chlamydial Infections in Humans, Bordeaux, France
  2. 2INRA, USC EA3671, Mycoplasmal and Chlamydial Infections in Humans, Bordeaux, France
  3. 3CHU de Bordeaux, National Reference Center for bacterial Sexually Transmitted Infections, Bordeaux, France
  4. 4CHU de Bordeaux, Infectious and Tropical Diseases Department, Bordeaux, France
  1. Correspondence to Dr Olivia Peuchant, USC EA3671, Mycoplasmal and Chlamydial Infections in Humans, University of Bordeaux Faculty of Medical Sciences, Bordeaux 33076, France; olivia.peuchant{at}u-bordeaux.fr

Abstract

Objectives We evaluated the prevalence of lymphogranuloma venereum (LGV) in anorectal Chlamydia trachomatis-positive French men who have sex with men (MSM) using pre-exposure prophylaxis (PrEP) for HIV. Here, we describe the clinical, biological and behavioural characteristics of these patients.

Methods Laboratories throughout French metropolitan areas performing routine testing for C. trachomatis sent positive anorectal specimens to the National Reference Centre for bacterial STIs for LGV real-time PCR targeting the pmpH gene. Identification of the C. trachomatis genovar was performed by ompA gene sequencing. For each patient, clinical, biological and sexual behaviour data were collected after obtaining written informed consent.

Results In 2017, 486 anorectal C. trachomatis-positive specimens from MSM PrEP users were analysed. A strain of genovar L was detected in 91 cases (18.7%). Patients with LGV were significantly more symptomatic, had more sexual partners and more concurrent syphilis compared with their non-LGV counterparts. OmpA gene sequencing, successful in two-thirds of anorectal C. trachomatis-positive specimens, showed that the LGV cases were mainly of variant L2b (n=33), followed by genovar L2 (n=27) and genetic L2b ompA variants (n=16). In 11 cases, the results indicated the occurrence of genetic exchange between L and non-L genovars.

Conclusions LGV was diagnosed in 18.7% of anorectal C. trachomatis-positive specimens from French MSM using PrEP. LGV testing should be carried out for MSM diagnosed with chlamydia and with a large number of sexual partners, high-risk practices and anorectal symptoms. These patients should be presumptively treated as having LGV. This is the first surveillance study of LGV among MSM PrEP users and monitoring should continue.

  • chlamydia trachomatis
  • HIV pre-exposure prophylaxis
  • lymphogranuloma venereum
  • molecular epidemiology
View Full Text

Statistics from Altmetric.com

Footnotes

  • Handling editor Nigel Field

  • Contributors OP and BdB designed and coordinated the study. AT and NH performed analyses. CL-N analysed and interpreted the data. OP, BdB, CC and CB interpreted the data and wrote the manuscript. All authors read, commented and approved the manuscript.

  • Funding This study was supported by an internal funding.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.